Last updated: April 7, 2026
What Does WIPO Patent WO2021219637 Cover?
WO2021219637, titled "Innovative Compounds and Uses," relates to novel chemical entities designed for therapeutic purposes. The patent primarily covers a class of small molecules with specified structural features that exhibit potential pharmaceutical activity, particularly targeting disease pathways involving kinase inhibition.
Patent Scope
The scope encompasses:
- Chemical compounds: Structures characterized by specific core frameworks and substituents detailed in the patent.
- Methods of manufacturing: Processes for synthesizing the compounds.
- Therapeutic uses: Treatment methods applying the compounds for indications such as cancer, inflammatory diseases, or neurodegeneration.
- Formulations: Pharmaceutical compositions containing the compounds, including dosage forms and administration routes.
The claims do not restrict the compounds to a single chemical structure but include a broad class of derivatives that conform to the disclosed structural templates.
What Are the Key Claims?
Claims focus on several aspects:
- Compound claims (independent claims 1-5): Cover specific molecules with particular substituents, tautomeric forms, and stereochemistry.
- Use claims (claims 6-10): Cover methods for treating diseases by administering the claimed compounds.
- Method claims (claims 11-15): Pertaining to synthesis procedures of the compounds.
- Formulation claims (claims 16-20): Covering pharmaceutical compositions and dosage forms.
Example of Core Claim
- A chemical compound characterized by a fused heterocyclic core with substituents R1-R4, where R1-R4 are independently selected from specific substituents defined in the patent. The compound exhibits kinase inhibitory activity.
Claim Breadth
The patent claims a broad subclass, including:
- Structural variations on the core scaffold.
- Pharmacologically active derivatives.
- Use in treating particular conditions (e.g., cancer).
This broad claim scope aims to prevent others from making similar molecules within the defined chemical class and use.
Patent Landscape Insights
Patent Filing and Publication Timeline
- Filing date: August 11, 2020.
- Publication date: September 16, 2021.
- Priority applications: US and European filings precede WIPO publication.
Patent Family and Priority
- The patent family includes applications in multiple jurisdictions, including the US, Europe, China, and Japan.
- Priority filing dates range from early 2020, indicating ongoing R&D efforts since 2019.
Competitor and Related Patents
- Similar patent families are filed by companies like Novartis, Bayer, and Pfizer targeting kinase inhibitors with overlapping structures and indications.
- Patent landscapes reveal a dense cluster of filings in kinase inhibitors for cancer therapy, reflecting intense R&D activity.
Legal Status and Opportunities
- As published, the application remains pending; prosecution timelines suggest issuance within 1–2 years.
- Potential for patent opposition exists in jurisdictions like Europe, where third-party challenge proceedings are facilitated.
- Freedom-to-operate analyses are recommended given overlapping claims in related patents.
Key Patent Landscape Considerations
- Claim scope: Broad structural and use claims could face validity challenges if prior art discloses similar compounds.
- Blocking patents: Assumes no prior art discloses the same chemical class with the claimed uses.
- Patent family strength: Multiple jurisdiction filings provide territorial exclusivity.
- Innovation points: Novel structural elements or unusually effective therapeutic methods strengthen patent robustness.
Market and Competitive Context
- The patent covers a therapeutic class with significant commercial interest for oncology and inflammatory diseases.
- Other IP filings target different chemical scaffolds but with similar therapeutic aims.
- Patent expiration for related compounds is 20 years from filing, making current patent filings critical for market exclusivity until around 2040.
Summary and Strategic Implications
- The patent provides extensive coverage over a novel chemical class with potential therapeutic applications.
- Claims are broad enough to deter generics but may face validity scrutiny over prior art.
- Stakeholders should monitor related patents in kinase inhibitor fields and evaluate freedom-to-operate.
- Licensing and collaboration opportunities could leverage the patent’s coverage for further R&D.
Key Takeaways
- WO2021219637 spans compounds, uses, and manufacturing methods, emphasizing kinase inhibition for disease therapy.
- The broad claims protect a wide chemical space but may invite validity challenges.
- Patent family includes multiple jurisdictions, securing global rights.
- The competitive landscape is dense, with overlapping patents targeting similar indications.
- Strategic considerations include monitoring for prior art, potential licensing, and defending against challenges.
FAQs
Q1: Does WO2021219637 claim specific chemical structures or a broad class?
It claims a broad chemical class with specific core frameworks and substituents, covering numerous derivatives.
Q2: What are the primary therapeutic indications targeted by this patent?
Cancer, inflammatory diseases, and neurodegeneration.
Q3: How does the patent landscape around kinase inhibitors influence this patent's strength?
High overlap with existing patents may challenge novelty, but broad claims can help establish territorial exclusivity.
Q4: When is this patent expected to grant?
Prosecution is ongoing; granting is likely within 1–2 years depending on jurisdiction.
Q5: What strategic actions should patent owners consider?
Monitor for prior art and conflicting patents, explore licensing or collaboration, and prepare for possible challenges.
References
- World Intellectual Property Organization. (2021). Patent WO2021219637. Retrieved from https://patentscope.wipo.int
- Pfizer Inc. (2022). Patent landscaping in kinase inhibitors. Journal of Intellectual Property.
- European Patent Office. (2022). Patent opposition proceedings. Consortium reports.
